NCT07091630
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Study sites: 94 to 95
- Minor Trial sites expanded: 89 → 94 locations
- Minor Site contacts updated at 1 of 89 sites
- Minor Trial sites expanded: 85 → 89 locations
- Minor Trial sites expanded: 82 → 85 locations
- Site details revised at 24 of 85 sites
- Minor Study sites: 82 to 85
- Notable Eligibility criteria expanded, about 10 words
- Trial sites expanded: 78 → 82 locations
- Secondary endpoints: details revised at 11 of 22 entries
- Minor Trial sites expanded: 71 → 78 locationsv11
- Minor Trial sites expanded: 61 → 71 locationsv10
- Minor Trial sites expanded: 56 → 61 locationsv9
- Minor Trial sites expanded: 43 → 56 locationsv8
- Minor Trial sites expanded: 19 → 43 locationsv7
- Minor Study sites: 14 to 19v6
- Minor Study sites: 9 to 14v5
- Minor Study sites: 2 to 9v4
- Minor Study sites: 1 to 2v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria expanded, about 26 words
- Study sites: 0 to 1
- Start date changed from estimate of Sep 2025 to Sep 16, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (22)
Show 17 moreShow less
Arms and interventions
Participants receive empasiprubart during part A
Participants receive placebo during part A
Participants receive empasiprubart during part B. Participants from the empasiprubart arm in part A will receive placebo once to maintain the blind of part A.
Biologicals: Empasiprubart IV
Other: Placebo IV
Sites
95 sites in 25 countries
United States 14, China 9, Georgia 8, Italy 8, Brazil 7, Bulgaria 5, France 5, Japan 4, Romania 4, United Kingdom 4, Argentina 3, Colombia 3, Poland 3, Slovakia 3, Austria 2, Greece 2, Israel 2, South Korea 2, Czechia 1, Denmark 1, Estonia 1, Hungary 1, Moldova 1, Netherlands 1, Singapore 1